"intra-cerebral haemorrhage"
Conditions
Interventions
1. No intervention (reference group)
2. Induced hypertension: increasing the mean arterial pressure with a maximum
of 30 mmHg with norepinephrine. In addition, the maximum MAP in these patients
will
Sponsors
Universitair Medisch Centrum Utrecht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Admission to the hospital 2. Age 18 years or over 3. Aneurysmal SAH, demonstrated on CT-angiography or cerebral agiograph, with onset less than 72 hours before admission 4. Glascow Coma Sum Score above 8. 5. DCI (decrease of 2 GSC points or all new neurological focal deficits), diagnosed by a neurologist, neurosurgeon or intensivist within 3 hours after deterioration. 6. Informed consent
Exclusion criteria
Exclusion criteria: 1. Symptomatic cerebral aneurysm not yet treated by coiling or clipping 2. Co-existing severe head injury. 3. A history of a cardiac rhythm disorder, necessitating medical treatment. 4. A history of a left ventricular pump failure, necessitating medical treatment. 5. Pregnancy. 6. Known allergy for CT-contrast agents. 7. Renal failure, defined as a serum creatinine > 150 µmol/l 8. Other causes cause for neurological deterioration (see page 15 of the study protocol for the differential diagnosis) 9. Severe hypertension, defined as a MAP of 120 mmHg or higher
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. To test whether it is feasible to perform a multicentre randomised controlled trial on induced hypertension to improve neurological outcome after SAH. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Number of patients experiencing DCI as a proportion of the total amount of SAH patients. 2. Reasons for exlusion 3. Number of patients (in retrospective) with other causes of neurological deterioration. 4. Difference in cerebral haemodynamics between the intervention groups. 5. Neurological condition at the start and end of the study period. 6. Neurological condition at 6 weeks after SAH. 7. Number of complications and adverse events. | — |
Countries
Netherlands
Outcome results
None listed